CytomX Therapeutics (CTMX)
(Delayed Data from NSDQ)
$1.19 USD
+0.02 (1.71%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.18 -0.01 (-0.84%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
CytomX Therapeutics, Inc. [CTMX]
Reports for Purchase
Showing records 41 - 60 ( 158 total )
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Solid Preclinical EpCAM ADC Data at World ADC Conference; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial BMS-986249 Phase 1 Data Looks Decent; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Clinical Focus on Partner Programs Following Restructuring
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Financials; Clinical Data Catalysts in Late 2022; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Restructuring to Extend Cash Runway into 2025; Two INDs for 2H:23
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Restructuring Extends Operational Runway Into 2025; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Disappointing Phase 2 Data; Higher Dosing Halted; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Downgrading to NEUTRAL and Reducing PT to $2; Pral Rav Hits and Misses
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Data Updates Ahead for Lead Programs
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; Initial Ph 2 Praluzatamab Data on Track for 2H:2022
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial CX-2029 Phase 2 Data Underwhelm, in Our View; Modulating PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: CytomX Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2021 Abstract Roundup For Covered CompaniesThis report contains brief updates on the following: ACET, ALPN, ANAB, BCEL, BEAM, CDAK, CTMX, FATE, IGMS, MRSN. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D